Intec Pharma is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology which releases drugs in a controlled manner towards the upper part of the gastrointestinal tract where it is absorbed. Intec Pharma’s product pipeline includes an Accordion Pill for cannabinoid therapies.
Location: Israel, Jerusalem District, Jerusalem
Employees: 11-50
Founded date: 2000
Investors 2
| Date | Name | Website |
| - | Shavit Cap... | shavitcapi... |
| - | Avoro Capi... | avorocapit... |
Mentions in press and media 9
| Date | Title | Description |
| 03.09.2024 | Parkinson’s Disease Drug Market: Trends, Growth, and Segmentation | Share Tweet Share Share Email Parkinson’s disease, a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, affects millions of individuals worldwide. As the global population age... |
| 03.08.2021 | Intec Pharma : Announces Expected Closing Date of Decoy Merger | JERUSALEM, Aug. 3, 2021 /PRNewswire/ -- Intec Parent, Inc. (NASDAQ: NTEC) ("Intec Parent" or the "Company"), today announced that the pending and previously announced reverse merger (the "Decoy Merger") with De... |
| 26.07.2021 | Intec Pharma : Announces $30 Million Private Placement Ahead of Decoy Merger | JERUSALEM, July 26, 2021 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec Israel" or the "Company"), today announced that its wholly-owned subsidiary, Intec Parent, Inc. ("Intec US"), entered into a sec... |
| 15.03.2021 | Intec Pharma and Decoy Biosystems Announce Merger Agreement | JERUSALEM, March 15, 2021 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") announced today that it has entered into a definitive agreement for a business combination with Decoy Biosystems, Inc.... |
| 15.03.2021 | Intec Pharma and Decoy Biosystems Announce Merger Agreement | JERUSALEM, March 15, 2021 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") announced today that it has entered into a definitive agreement for a business combination with Decoy Biosystems, Inc.... |
| 05.11.2020 | Intec Pharma Reports Third Quarter 2020 Financial Results and Provides Corporate Update | JERUSALEM, Nov. 5, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the third quarter ended September 30, 2020 and provides a corporate update. "... |
| 05.08.2020 | Intec Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate Update | JERUSALEM, Aug. 5, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the second quarter ended June 30, 2020 and provides a corporate update. "We h... |
| 11.12.2019 | Battered, cash hungry Intec feels the burn of Novartis rejection | It’s a case of some bad timing for Intec. Just when a key trial testing the company’s Accordion drug delivery tech imploded in Parkinson’s disease, they handed Novartis data from a successful PK study of a custom Accor... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |